Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

5,185 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
The combined evaluation of interim contrast-enhanced computerized tomography (CT) and FDG-PET/CT predicts the clinical outcomes and may impact on the therapeutic plans in patients with aggressive non-Hodgkin's lymphoma.
Yang DH, Min JJ, Jeong YY, Ahn JS, Kim YK, Cho SH, Chung IJ, Bom HS, Kim HJ, Lee JJ. Yang DH, et al. Among authors: lee jj. Ann Hematol. 2009 May;88(5):425-32. doi: 10.1007/s00277-008-0616-3. Epub 2008 Nov 12. Ann Hematol. 2009. PMID: 19002686 Clinical Trial.
Prognostic factors and clinical outcomes of high-dose chemotherapy followed by autologous stem cell transplantation in patients with peripheral T cell lymphoma, unspecified: complete remission at transplantation and the prognostic index of peripheral T cell lymphoma are the major factors predictive of outcome.
Yang DH, Kim WS, Kim SJ, Bae SH, Kim SH, Kim IH, Yoon SS, Mun YC, Shin HJ, Chae YS, Kwak JY, Kim H, Kim MK, Kim JS, Won JH, Lee JJ, Suh CW. Yang DH, et al. Among authors: lee jj. Biol Blood Marrow Transplant. 2009 Jan;15(1):118-25. doi: 10.1016/j.bbmt.2008.11.010. Biol Blood Marrow Transplant. 2009. PMID: 19135950 Free article.
Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study.
Kim YK, Sohn SK, Lee JH, Yang DH, Moon JH, Ahn JS, Kim HJ, Lee JJ; Korean Multiple Myeloma Working Party (KMMWP). Kim YK, et al. Among authors: lee jh, lee jj. Ann Hematol. 2010 May;89(5):475-82. doi: 10.1007/s00277-009-0856-x. Epub 2009 Nov 18. Ann Hematol. 2010. PMID: 19921192 Clinical Trial.
Induction treatment with cyclophosphamide, thalidomide, and dexamethasone in newly diagnosed multiple myeloma: a phase II study.
Yang DH, Kim YK, Sohn SK, Chung JS, Joo YD, Lee JH, Lee JL, Ahn JS, Moon JH, Shin HJ, Choi YJ, Lee WS, Kim HJ, Lee JJ; Korean Multiple Myeloma Working Party. Yang DH, et al. Among authors: lee ws, lee jh, lee jj, lee jl. Clin Lymphoma Myeloma Leuk. 2010 Feb;10(1):62-7. doi: 10.3816/CLML.2010.n.007. Clin Lymphoma Myeloma Leuk. 2010. PMID: 20223731 Clinical Trial.
Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety.
Lee SS, Suh C, Kim BS, Chung J, Joo YD, Ryoo HM, Do YR, Jin JY, Kang HJ, Lee GW, Lee MH, Shim H, Kim K, Yoon SS, Bang SM, Kim HY, Lee JJ, Park J, Lee DS, Lee JH; Korean Multiple Myeloma Working Party. Lee SS, et al. Among authors: lee mh, lee ds, lee jh, lee gw, lee jj. Ann Hematol. 2010 Sep;89(9):905-12. doi: 10.1007/s00277-010-0943-z. Epub 2010 Mar 27. Ann Hematol. 2010. PMID: 20349060 Clinical Trial.
Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study.
Kang HJ, Kim WS, Kim SJ, Lee JJ, Yang DH, Kim JS, Lee SR, Lee GW, Kim HJ, Kim HY, Oh SY, Kim HC, Eom HS, Chung J, Park J, Suh C, Ryoo BY. Kang HJ, et al. Among authors: lee sr, lee jj, lee gw. Ann Hematol. 2012 Apr;91(4):543-51. doi: 10.1007/s00277-011-1337-6. Epub 2011 Sep 16. Ann Hematol. 2012. PMID: 21922208 Clinical Trial.
5,185 results